Esperion Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question and answer session. Please be advised that today's conference call will be recorded. I would now like to hand the conference over to Tiffany Aldrich, Head of Corporate Communications for Spherian Therapeutics. Please go ahead.

Thank you, operator. Good morning and welcome to Experian's fourth quarter and full year 2025 earnings conference call. With us today are Sheldon Koenig, President and CEO, and Ben Halliday, CFO. Other members of the executive team will be available for Q&A following our prepared remarks. We issued a press release earlier this morning detailing the content of today's call. A copy can be found on the investor page of our website, together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and in our SEC filing. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast March 10, 2026. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast. As a reminder, this conference call and webcast are being recorded and archived. We will begin the call with prepared remarks and then open the line for your questions. I'll now turn the call over to Sheldon.

Thank you, Tiffany. Good morning, everyone, and thank you for joining us. 2025 was a defining and transformative year for our company, representing our strongest performance to date. We fortified our financial foundation, continued our strong commercial execution, and reinforced our commitment to the patient to inspire everything we do. Because of this work, we entered 2026 with strong momentum and a clear path forward. We recently introduced our vision 2040, which defines our long-term ambition and the roadmap to achieve it. I'm proud to say we are already executing on that vision. Our planned acquisition of Corsatius Therapeutics significantly enhances our company and demonstrates our Vision 2040 strategy in action. It is a transformational step that will give us two powerful global franchises to grow. our global benfidoic acid portfolio, and Endymus, a first-in-class intranasal diuretic addressing meaningful needs in heart failure care. This combination of addressing bad cholesterol and heart failure will align with our existing cardiology footprint, accelerate growth, and most importantly, offer patients more impactful, patient-friendly options across the continuum of cardiometabolic disease. The acquisition of Corstasys is a catalyst for additional long-term value and a testament to our commitment to building a larger and sustainably profitable company. Our priority is to grow these two franchises to their multi-billion dollar potential. Turning to the progress we've made building the U.S. Bempatoic Acid franchise, we achieved strong prescription growth and broadened payer coverage as we focused our sales and marketing efforts on statin-intolerant patients, which represents a significant market opportunity. Together, this allowed us to drive Q4 year-over-year sales by 38%, increase retail prescription equivalents by 34%, and expand the number of unique healthcare practitioners prescribing Nexatol and Nexavet by nearly 25%. We anticipate 2026 to continue this momentum driven by our strong reimbursement and expect favorable positioning in the U.S. dyslipidemia guidelines, which should be released imminently. In addition, the American College of Cardiology Scientific Statement on Inflammation and Cardiovascular Disease formally recognized the link between inflammation measured by HSCRP and ASCBD. The authors provided call to action to implement broad screening of HSCRP for primary and secondary prevention patients in combination with LDL cholesterol screening. Importantly, the American Heart Association corroborated this recognition in its HSCRP toolkit for professionals in which benvodoic acid is recognized as an agent to reduce HSCRP. I will remind everyone that Nexlatal and Nexlazet are the only non-statins proven to reduce HSCRP by up to 46%. Looking ahead, we are advancing our two triple combination programs and expect to complete the clinical and regulatory requirements to commercialize in 2027. Based on published data, triple combination therapies have demonstrated the potential to reduce LDL cholesterol up to 70%, a level of efficacy that could rival current injectables and emerging oral treatments. Now turning to our continued international expansion. Our global partners delivered yet another year of substantial growth. Daiichi Sankyo Europe increased fourth quarter royalty revenue by 51% compared with fourth quarter 2024. They expanded access to 30 countries, including receiving favorable payer reimbursement and launching in France, and have treated more than 700,000 patients to date. During the fourth quarter, our Japanese partner, Otsuka, successfully launched Nexlatol in Japan following regulatory approval and a highly favorable national health insurance price listing. Early market reception has exceeded even the most optimistic expectations. With Japan representing the world's third largest market for cardiovascular disease prevention, and given the strong pricing environment, we believe this momentum positions us for significant and sustained growth in 2026 and beyond. Additional launches and regulatory progress continue across Canada, Israel, Australia, and New Zealand. Moving on to our pipeline progress, we continue to advance a new generation of highly specifically ACLY inhibitors targeting serious metabolic and inflammatory diseases. We nominated ESP2001 as our next development candidate for the treatment of primary sclerosing cholangitis, or PSE, a devastating disease with no approved therapies. ESP2001 is now advancing through IND enabling studies, and we plan to be in the clinic by the end of this year. Collectively, our progress across commercial execution, pipeline advancement, and global expansion reinforces the strength of the strategy we have put in place and sets us up for a powerful next phase of growth. Now let me turn to a review of our exciting agreement to acquire Corstasis Therapeutics. This transaction will provide us with global rights to its FDA-approved therapy, EnviMist, a first-in-class intranasal diuretic approved in September 2025 for the treatment of edema associated with congestive heart failure, hepatic disease, and renal disease. This acquisition is a highly strategic and transformational step for Aspirion. It will expand our presence beyond chronic lipid management into a large complementary cardiometabolic market and meaningfully accelerate our growth trajectory. In addition, CoreStasis is advancing a subcutaneous pipeline including a multi-dose pen injector which has the potential to unlock additional market opportunities. MVMS is available now to address a significant unmet need and aligns directly with RUS cardiology-focused commercial infrastructure, enabling immediate cross-selling synergies with the physicians already prescribing Nexotol and Nexlovet. MVMS was developed in partnership with cardiologists specializing in heart failure who recognized the fact that one in four patients are readmitted to a hospital within 30 days, driving significant healthcare costs, despite current products in the market attempting to address this. To reduce readmission rates and provide an easy-to-use at-home treatment, these cardiologists developed Embumis, a differentiated, patient-friendly alternative to oral and injectable diuretics. As the only nasal spray loop diuretic, it bypasses GI absorption issues, offers rapid onset, and supports at-home management of fluid overload. This creates a compelling opportunity to reduce hospital admissions and readmissions, an area of profound unmet need and heart failure, where nearly two-thirds of the one million hospitalizations each year are primarily for diuresis, many of which may be avoidable. Financially, this acquisition provides Aspirion with a highly attractive entry point into a four-plus-billion-dollar U.S. outpatient market, a significant runway for utilization growth. Moving forward, our plan is to fully leverage our commercial team's cardiovascular sales presence to scale adoption and accelerate revenue contribution. We are also planning our strategy to launch NVMIST in ex-U.S. markets as we have global rights. The transaction is expected to close in the second quarter of 2026. MPMS strengthens our foundation, expands our commercial reach, and uniquely positions us to attack the growing global cardiometabolic disease epidemic now and into the future. With that, let me turn the call over to our Chief Financial Officer, Ben Halliday, for a review of our financials.